NUTEX HEALTH REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS

Nine-month cash spending on stock repurchases and retirements totaled $50.689 million.

Rhea-AI Summary

Nutex Health (NUTX) reported third-quarter 2026 attributable net income of $40.2 million, down from the same quarter a year earlier. Diluted earnings per share fell to $5.71 from $7.76, while revenue decreased 18.7% to $217.6 million. Hospital visits rose 18.1%, but same-hospital revenue declined 20.1%. Operating cash flow fell to $78.3 million from $99.5 million.

For the nine months ended September 30, 2026, attributable net income increased 159% to $152.9 million, while revenue fell 10.9% to $644.9 million. Lower stock-based compensation primarily drove the earnings increase. A $52.3 million non-cash expense reduction also increased attributable net income by $25.0 million. Nine-month operating cash flow reached $188.1 million. Cash totaled $249.9 million, versus $185.6 million at year-end 2025; long-term debt, net, rose to $34.2 million from $29.2 million. The company expects two hospital openings in the fourth quarter.

16 points · 0 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 15 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate pointNine-month attributable net income increased 159% to $152.9 million; diluted EPS rose to $21.50 from $8.87.
• Moderate pointStock repurchases and retirements used $50.689 million in cash during the first nine months of 2026. 3.6% of market cap
• Moderate pointNine-month operating income increased to $280.1 million from $244.7 million in 2025.
• Moderate pointHospital visits rose 18.1% to 54,622 in Q3; nine-month visits rose 10.2% to 154,326.
• Moderate pointArbitration costs fell to $27.8 million in Q3 and $61.4 million over nine months, from $41.9 million and $116.2 million.
• Moderate pointNine-month EBITDA, a non-GAAP earnings measure, rose to $225.8 million from $142.9 million.

10 minor points

• Minor pointNine-month operating cash flow increased to $188.1 million from $177.7 million in 2025.
• Minor pointCash and equivalents rose to $249.9 million at September 30, 2026, from $185.6 million at year-end 2025.
• Minor pointNine-month stock-based compensation fell to $6.4 million from $119.6 million, primarily driving attributable earnings growth.
• Minor pointNon-cash contract-services expense reduction of $52.3 million increased nine-month attributable net income by $25.0 million.
• Minor pointSame-hospital visits increased 12.4% in Q3 and 6.3% over nine months, year over year.
• Minor pointPopulation health revenue increased to $8.516 million in Q3 and $26.331 million over nine months, from $7.565 million and $23.090 million.
• Minor pointQ3 stock-based compensation decreased to $7.388 million from $13.217 million a year earlier.
• Minor pointNet interest expense fell to $4.862 million in Q3 and $14.215 million over nine months, from $5.452 million and $17.250 million.
• Minor pointIncome tax expense fell to $15.197 million in Q3 and $49.762 million over nine months, from $27.140 million and $55.138 million.
• Minor point. Forward-looking: it has not happened yet and may not happen.Nutex Health expects two new hospital openings in the fourth quarter of 2026.

Negative

• Moderate pointQ3 attributable net income fell to $40.2 million from $55.4 million; diluted EPS declined to $5.71 from $7.76.
• Moderate pointRevenue fell 18.7% to $217.6 million in Q3 and 10.9% to $644.9 million over nine months.
• Moderate pointQ3 operating cash flow fell to $78.3 million from $99.5 million a year earlier.
• Moderate pointQ3 operating income declined to $77.098 million from $130.367 million a year earlier.
• Moderate pointGross profit fell to $101.526 million in Q3 and $334.535 million over nine months, from $154.881 million and $398.143 million.
• Moderate pointAdjusted EBITDA, a non-GAAP earnings measure, fell to $63.9 million in Q3 and $211.4 million over nine months, from $98.5 million and $243.0 million.

9 minor points

• Minor pointHospital division revenue fell to $209.097 million in Q3 and $618.519 million over nine months, from $260.239 million and $700.488 million.
• Minor pointSame-hospital revenue declined 20.1% in Q3 and 11.2% over nine months, year over year.
• Minor pointQ3 EBITDA declined to $63.3 million from $91.8 million a year earlier.
• Minor pointPayroll increased to $48.415 million in Q3 and $132.605 million over nine months, from $38.817 million and $109.961 million.
• Minor pointGeneral and administrative expenses increased to $17.040 million in Q3 and $48.097 million over nine months, from $11.297 million and $33.830 million.
• Minor pointMedical supplies expense increased to $4.132 million in Q3 and $13.483 million over nine months, from $3.307 million and $11.920 million.
• Minor pointOther operating expenses increased to $14.227 million in Q3 and $42.491 million over nine months, from $11.959 million and $34.610 million.
• Minor pointDepreciation and amortization increased to $5.622 million in Q3 and $16.431 million over nine months, from $5.003 million and $15.343 million.
• Minor pointLong-term debt, net, rose to $34.2 million at September 30, 2026, from $29.2 million at year-end 2025.

News Explained

For the nine months ended September 30, 2026, Nutex Health reported a $50,689 thousand cash outflow related to stock repurchases and retirements; common shares outstanding were 6,857,504 at period-end, down from 7,086,670 on December 31, 2025.

Key Figures

Third-quarter revenue: $217.6 million, down 18.7% Third-quarter attributable net income: $40.2 million Hospital Division visits: 54,622, up 18.1% +5 more

Third-quarter revenue

$217.6 million, down 18.7%

Three months ended September 30, 2026; compared with $267.8 million in 2025

Third-quarter attributable net income

$40.2 million

Three months ended September 30, 2026; compared with $55.4 million in 2025

Hospital Division visits

54,622, up 18.1%

Three months ended September 30, 2026; year over year

Nine-month revenue

$644.9 million, down 10.9%

Nine months ended September 30, 2026; compared with $723.6 million in 2025

Nine-month attributable net income

$152.9 million

Nine months ended September 30, 2026; includes the described change in estimate

Contract services expense reduction

$52.3 million

Non-cash reduction from a change in estimate for the nine-month period

Attributable net income impact of estimate change

$25.0 million increase

Nine months ended September 30, 2026; the company also reported a $4.83 per diluted share impact

Nine-month operating cash flow

$188.1 million

Nine months ended September 30, 2026; compared with $177.7 million in 2025

Previous Earnings Reports

3 past events · Latest: Aug 06

Same Type 3 events

1. Aug 06

   Q2 earnings

   24h Move

   +6.7%

   Reported quarterly profitability and hospital-visit growth despite lower revenue.

2. Apr 30

   Q1 earnings

   24h Move

   +17.1%

   Reported year-over-year revenue growth and positive attributable net income.

3. Nov 19

   Q3 earnings

   24h Move

   +26.9%

   Reported year-over-year revenue growth and positive attributable net income.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

diluted eps, ebitda, adjusted ebitda, non-gaap, +1 more

5 terms

diluted eps financial

"diluted EPS of $5.71"

Diluted earnings per share (EPS) shows how much profit a company makes for each share of stock, assuming all possible shares from stock options or convertible securities are used. It provides a more conservative estimate than basic EPS, accounting for potential share increases that could dilute ownership. Investors use diluted EPS to get a clearer picture of a company's true profitability on a per-share basis.

ebitda financial

"EBITDA attributable to Nutex Health was $63.3 million"

EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It measures a company's profitability by focusing on the money it makes from its core operations, ignoring expenses like taxes and accounting adjustments. Investors use EBITDA to compare how well different companies are performing financially, as it provides a clearer picture of operational success without the influence of financial structure or accounting choices.

View in glossary

adjusted ebitda financial

"Adjusted EBITDA attributable to Nutex Health was $63.9 million"

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

non-gaap financial

"EBITDA and Adjusted EBITDA are non-GAAP financial metrics."

Non-GAAP refers to financial measures that companies use to show their earnings or performance without including certain expenses or income that are often added back to give a different picture. It matters because it can make a company's results look better or more favorable, but it may also hide important costs, so investors need to look at both GAAP (official rules) and non-GAAP numbers to get a full understanding.

View in glossary

stock-based compensation financial

"Total stock-based compensation expense for the nine months ended"

Stock-based compensation is when a company pays employees, directors or consultants with shares or the right to buy shares instead of or in addition to cash. It matters to investors because issuing stock or options spreads ownership thinner (like cutting a pie into more slices), which can reduce each existing share’s claim on profits and can also change reported earnings; investors watch it to assess true cost of running the business and how management is incentivized.

View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HOUSTON, Nov. 5, 2026 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ and Nasdaq Texas: NUTX), today announced financial results for the three and nine months ended September 30, 2026. Nutex Health is a physician-led, healthcare services and operations company with 28 hospital facilities in 12 states (hospital division), and a primary care-centric, risk-bearing population health management division.

Financial review for the three months ended September 30, 2026:

• Net income attributable to Nutex Health was $40.2 million, or diluted EPS of $5.71, compared to $55.4 million, or diluted EPS of $7.76, for the three months ended September 30, 2025.
• EBITDA attributable to Nutex Health was $63.3 million and Adjusted EBITDA attributable to Nutex Health was $63.9 million, compared to $91.8 million and $98.5 million, respectively, for the three months ended September 30, 2025.
• Total visits at the Hospital Division increased 18.1% year over year to 54,622, while visits at same hospitals, which are hospitals that were opened by December 31, 2024, increased 12.4%.
• Net cash provided by operating activities was $78.3 million for the three months ended September 30, 2026, as compared to $99.5 million for the same period in 2025.

Financial review for the nine months ended September 30, 2026:

• Net income attributable to Nutex Health increased to $152.9 million, or diluted EPS of $21.50, compared to $59.0 million, or diluted EPS of $8.87, for the nine months ended September 30, 2025.
• EBITDA attributable to Nutex Health was $225.8 million and Adjusted EBITDA attributable to Nutex Health was $211.4 million (including the $52.3 million non-cash reduction to contract services expense resulting from the change in estimate described below), compared to $142.9 million and $243.0 million, respectively, for the nine months ended September 30, 2025.
• Total visits at the Hospital Division increased 10.2% year over year to 154,326, while visits at same hospitals increased 6.3%.
• Net cash provided by operating activities was $188.1 million for the nine months ended September 30, 2026, as compared to $177.7 million for the same period in 2025; and as of September 30, 2026, the Company had long-term debt, net of $34.2 million, compared to $29.2 million as of December 31, 2025.
• As of September 30, 2026, the Company had total assets of $1.0 billion, including cash and cash equivalents of $249.9 million, as compared to $918.5 million in total assets and $185.6 million in cash and cash equivalents as of December 31, 2025.

Note: EBITDA and Adjusted EBITDA are non-GAAP financial metrics. A reconciliation of non-GAAP to GAAP measures is included below in this earnings release.

Total revenue decreased 10.9% to $644.9 million for the nine months ended September 30, 2026, compared to $723.6 million for the same period in 2025, while hospital division revenue at same hospitals decreased 11.2%. Total revenue decreased 18.7% to $217.6 million for the three months ended September 30, 2026, compared to $267.8 million for the same period in 2025, while hospital division revenue at same hospitals decreased 20.1%. The decrease was primarily driven by factors that favorably impacted revenue recognized in 2025, including the availability of additional collection data that supported higher estimates for services rendered in 2024, and the reconciliation of certain ineligible charts during the fourth quarter of 2025 that had been included from mid-2024 through the first nine months of 2025.

Of the Company's billable visits, approximately 50-60% are submitted through the IDR process, with 40-50% of all billable visits resulting in an award determination. When an award determination is made, Nutex Health prevailed in over 80% of those determinations over the last nine months and collects, on average, over 80% of the award amounts as calculated on awards from inception through March of 2026.

For the three and nine months ended September 30, 2026, total cost of arbitration was $27.8 million and $61.4 million, respectively, compared to $41.9 million and $116.2 million for the same periods in 2025. Results for the nine months ended September 30, 2026 include a $52.3 million reduction to contract services expense resulting from a change in estimate related to the June 30, 2026 amendment to the Company's agreement with HaloMD and the reduction in the CMS administrative fee, which increased net income attributable to Nutex Health by $25.0 million, or $4.83 per diluted share.

Total stock-based compensation expense for the nine months ended September 30, 2026 was $6.4 million, compared to $119.6 million for the same period in 2025. Net income attributable to Nutex Health increased 159% in the first nine months of 2026 as compared to the same period in 2025, primarily due to lower stock-based compensation related to obligations for under-construction and ramping hospitals.

"2026 is continuing to be a solid financial year, including total revenue of $644.9 million, net income attributable to Nutex of $152.9 million, diluted EPS of $21.50 per share, and $188.1 million of operating cash flow in the first nine months of 2026. We also delivered meaningful operating income improvement, with operating income increasing to $280.1 million for the first nine months of 2026 from $244.7 million in the same period of 2025. Our balance sheet remains strong with a cash balance of $249.9 million and long-term debt of $34.2 million. We believe that we are well positioned to finish the year strong as we continue to grow with the expected opening of two new hospitals in the fourth quarter," stated Jon Bates, Chief Financial Officer of Nutex Health.

"We're very pleased with our progress in the first nine months of 2026. Patient volumes are growing across both existing hospitals and the overall network, while cash collections remain strong. Our de novo hospital development pipeline remains robust, with exciting growth opportunities ahead," stated Tom Vo, M.D., MBA, Chairman and Chief Executive Officer of Nutex Health.

For more details on the Company's financial results for the three and nine months ended September 30, 2026, please refer to our Quarterly Report on Form 10-Q filed with the U.S. Securities & Exchange Commission and accessible at www.sec.gov.

Conference Call on Third Quarter 2026 Results

The Company will host a conference call on Friday, November 6, 2026 at 9:30 a.m. CT to discuss its results for the first three quarters of 2026.

Participant Listening: 1-877-407-9208 or 1-201-493-6784

Participant Link: https://callme.viavid.com/viavid/?callme=true&passcode=13746493&h=true&info=company&r=true&B=6 

To access the call, please dial in approximately five minutes before the start time. Those who are unable to attend the live conference call may access the recording on the Company's website.

 

NUTEX HEALTH INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(In thousands, except share and per share amounts)		September 30, 2026		December 31, 2025
Assets
Current assets:
Cash and cash equivalents		$            249,911		$            185,574
Restricted cash and short-term investments		3,649		297
Accounts receivable		356,061		319,440
Accounts receivable - related parties		4,777		5,978
Inventories		5,144		2,866
Prepaid expenses and other current assets		13,700		24,656
Total current assets		633,242		538,811
Property and equipment, net (accumulated depreciation of 36,565 and 31,696 as of September 30, 2026 and December 31, 2025, respectively)		103,241		94,581
Operating lease right-of-use assets		22,897		26,955
Financing lease right-of-use assets		235,077		222,367
Intangible assets, net		20,255		21,230
Goodwill, net		13,919		13,919
Other assets		3,745		662
Total assets		$          1,032,376		$            918,525
Liabilities and Equity
Current liabilities:
Accounts payable		$             10,181		$             45,863
Accounts payable - related parties		5,220		3,104
Lines of credit		66		740
Current portion of long-term debt		8,104		13,336
Operating lease liabilities, current portion		1,998		2,152
Financing lease liabilities, current portion		7,092		7,077
Accrued arbitration expenses		51,276		49,743
Accrued income tax expense		3,965		867
Accrued stock-based compensation		11,549		8,256
Accrued expenses and other current liabilities		33,494		26,773
Total current liabilities		132,945		157,911
Long-term debt, net		34,200		29,174
Non-current operating lease liabilities, net		25,887		30,037
Non-current financing lease liabilities, net		287,635		268,877
Deferred tax liabilities		10,799		9,089
Total liabilities		491,466		495,088
Commitments and contingencies (Note 10)
Equity:
Common stock, $0.001 par value; 950,000,000 shares authorized; 6,857,504 and 7,086,670 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively		7		7
Additional paid-in capital		568,870		615,627
Accumulated deficit		(133,309)		(286,187)
Nutex Health Inc. equity		435,568		329,447
Noncontrolling interests		105,342		93,990
Total equity		540,910		423,437
Total liabilities and equity		$          1,032,376		$            918,525

 

NUTEX HEALTH INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
		Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands, except per share amounts)		2026		2025		2026		2025
Revenue:
Hospital division		$         209,097		$         260,239		$         618,519		$         700,488
Population health management division		8,516		7,565		26,331		23,090
Total revenue		217,613		267,804		644,850		723,578
Operating costs and expenses:
Payroll		48,415		38,817		132,605		109,961
Contract services		43,691		53,837		105,305		153,601
Medical supplies		4,132		3,307		13,483		11,920
Depreciation and amortization		5,622		5,003		16,431		15,343
Other		14,227		11,959		42,491		34,610
Total operating costs and expenses		116,087		112,923		310,315		325,435
Gross profit		101,526		154,881		334,535		398,143
Corporate and other costs:
Stock-based compensation		7,388		13,217		6,357		119,606
General and administrative expenses		17,040		11,297		48,097		33,830
Total corporate and other costs		24,428		24,514		54,454		153,436
Operating income		77,098		130,367		280,081		244,707
Interest expense, net		4,862		5,452		14,215		17,250
Other (income) expense		(304)		976		(319)		8,570
Income before taxes		72,540		123,939		266,185		218,887
Income tax expense		15,197		27,140		49,762		55,138
Net income		57,343		96,799		216,423		163,749
Less: net income attributable to noncontrolling interests		17,114		41,364		63,545		104,794
Net income attributable to Nutex Health Inc.		$          40,229		$          55,435		$         152,878		$          58,955
Earnings per common share:
Basic		$             5.87		$             8.27		$            22.05		$             9.63
Diluted		$             5.71		$             7.76		$            21.50		$             8.87

 

NUTEX HEALTH INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
		Nine Months Ended September 30,
(In thousands)		2026		2025
Cash flows from operating activities:
Net income		$        216,423		$        163,749
Adjustment to reconcile net income to net cash from operating activities:
Depreciation and amortization		16,431		15,343
Stock-based compensation expense		6,357		119,606
Changes to deferred taxes		1,710		22,942
Debt accretion expense		61		756
Non-cash effect of change in estimate		(52,319)		—
Changes in operating assets and liabilities:
(Increase)/Decrease in Accounts receivable		(36,621)		(154,960)
(Increase)/Decrease in Accounts receivable - related party		1,201		(3,751)
(Increase)/Decrease in Inventories		(2,278)		(308)
(Increase)/Decrease in Income tax receivable		—		(12,097)
(Increase)/Decrease in Prepaid expenses and other current assets		7,873		(6,376)
(Increase)/Decrease in Operating right-of-use assets		4,058		518
Increase/(Decrease) in Accounts payable		(4,013)		36,637
Increase/(Decrease) in Accounts payable - related party		2,116		3,276
Increase/(Decrease) in Operating lease liabilities		(4,304)		(164)
Increase/(Decrease) in Accrued arbitration expenses		22,183		16,571
Increase/(Decrease) in Accrued income tax expense		3,098		(26,533)
Increase/(Decrease) in Accrued expenses and other current liabilities		6,089		2,527
Net cash provided by operating activities		188,065		177,736
Cash flows from investing activities:
Acquisitions of property and equipment		(8,945)		(1,117)
Proceeds from restricted short-term investment		—		2,941
Cash related to asset acquisition		—		(1,994)
Net cash used in investing activities		(8,945)		(170)
Cash flows from financing activities:
Proceeds from lines of credit		—		5,043
Proceeds from notes payable		934		273
Repayments of lines of credit		(673)		(3,293)
Repayments of notes payable		(4,817)		(8,319)
Repayments of finance leases		(4,453)		(4,004)
Proceeds from exercise of warrants		250		—
Cash related to stock repurchases and retirements		(50,689)		—
Members' contributions		1,725		316
Members' distributions		(53,708)		(42,174)
Net cash used in financing activities		(111,431)		(52,158)
Net change in cash, cash equivalents, and restricted cash		67,689		125,408
Cash and cash equivalents - beginning of the period		185,574		40,640
Restricted cash and short-term investment - beginning of period		297		—
Cash and cash equivalents and restricted cash and short-term investment - beginning of period		185,871		40,640
Cash and cash equivalents - end of period		249,911		166,048
Restricted cash and short-term investment - end of period		3,649		—
Cash and cash equivalents and restricted cash and short-term investment - end of period		$        253,560		$        166,048

Non-GAAP Financial Measures

EBITDA and Adjusted EBITDA. EBITDA and Adjusted EBITDA are used as supplemental non-GAAP financial measures by management and external users of our financial statements, such as industry analysts, investors, lenders, and rating agencies. We believe EBITDA and Adjusted EBITDA are useful because these measures allow us to more effectively evaluate our operating performance.

We define EBITDA as net income attributable to Nutex Health Inc. plus interest expense, net, income taxes, depreciation, and amortization. Interest expense, net includes interest on lease liabilities, which is a component of total finance lease cost.

We define Adjusted EBITDA as net income attributable to Nutex Health Inc. plus interest expense, net, income taxes, depreciation and amortization, further adjusted for stock-based compensation, finance lease payments related to leases under Accounting Standards Codification Topic 842: Leases ("ASC 842"), certain defined items of expense and any acquisition-related costs and impairments. A reconciliation of net income to EBITDA and Adjusted EBITDA is included below.

Beginning in the first quarter of 2025, we have updated our presentation of Adjusted EBITDA to separately disclose finance lease payments related to leases under ASC 842. We believe this update provides greater transparency into our operating performance.

EBITDA and Adjusted EBITDA are not intended to serve as alternatives to U.S. GAAP measures of performance and may not be comparable to similarly-titled measures presented by other companies. EBITDA and Adjusted EBITDA follow (in thousands):

	Three Months Ended September 30,
	2026		2025
Reconciliation of net income attributable to Nutex Health Inc. to Adjusted EBITDA:
Net income attributable to Nutex Health Inc.	$           40,229		$           55,435
Depreciation and amortization	5,622		5,003
Interest expense, net	4,862		5,452
Income tax expense	15,197		27,140
Allocation to noncontrolling interests	(2,565)		(1,243)
EBITDA	63,345		91,787
Stock-based compensation	7,388		13,217
Finance lease payments	(6,856)		(6,474)
Adjusted EBITDA	$           63,877		$           98,530

 

	Nine Months Ended September 30,
	2026		2025
Reconciliation of net income attributable to Nutex Health Inc. to Adjusted EBITDA:
Net income attributable to Nutex Health Inc.	$         152,878		$           58,955
Depreciation and amortization	16,431		15,343
Interest expense, net	14,215		17,250
Income tax expense	49,762		55,138
Allocation to noncontrolling interests	(7,490)		(3,815)
EBITDA	225,796		142,871
Stock-based compensation	6,357		119,606
Finance lease payments	(20,727)		(19,512)
Adjusted EBITDA	$         211,426		$         242,965

About Nutex Health Inc.

Headquartered in Houston, Texas, Nutex Health Inc. (NASDAQ and Nasdaq Texas: NUTX) is a physician-led, healthcare services and operations company with three divisions: a Hospital Division, a Population Health Management Division, and a Real Estate Division.

The Hospital Division owns, develops, and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments. This division owns and operates 28 hospital facilities in 12 states.

The Population Health Management Division owns and operates provider networks such as Independent Physician Associations. Through our Management Services Organization, we provide management, administrative and other support services to our affiliated hospitals and physician groups.

The Real Estate division comprises of real estate entities along with activity related to the development and construction of hospital facilities. The real estate entities own the land and hospital buildings which are leased to our hospital entities.

Forward-Looking Statements

Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words or phrases "will," "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," "goal," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include, but are not limited to, regulatory and litigation uncertainty under the No Surprises Act, lawsuits filed by health insurance providers against our third party provider in the arbitration process, sales of a substantial amount of our Common Stock by our stockholders, our obligation to issue additional shares of our common stock to former doctor owners of under construction hospitals, manipulative short seller reports, the impact of litigation and disputes, including pending earn-out disputes, securities class actions, derivative actions and class actions related to the recent cybersecurity incident, impacts of the recent and potential future cybersecurity incidents, our ability to successfully execute our growth strategy, including the timing of new hospital openings, economic conditions, dependence on management, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company's ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Annual Report on Form 10-K for the year ended December 31, 2025 under the heading "Risk Factors" in Part I, Item 1A thereof, and in the Quarterly Reports on Form 10-Q for the periods ended March 31, 2026, June 30, 2026, and September 30, 2026, under the heading "Risk Factors" in Part II, Item 1A thereof, and the risk factors and other cautionary statements contained in our other filings with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.

View original content:https://www.prnewswire.com/news-releases/nutex-health-reports-third-quarter-2026-financial-results-302931337.html

SOURCE Nutex Health, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were Nutex Health's third-quarter 2026 earnings and revenue?

Nutex Health reported attributable net income of $40.2 million, diluted earnings per share of $5.71, and revenue of $217.6 million. A year earlier, attributable net income was $55.4 million and diluted earnings per share were $7.76. Revenue decreased 18.7% year over year.

Why did Nutex Health's revenue decline in 2026?

Nutex Health attributed the decline primarily to factors that favored revenue recognized in 2025. These included additional collection data supporting higher estimates for services rendered in 2024 and the fourth-quarter 2025 reconciliation of certain ineligible charts included from mid-2024 through the first nine months of 2025.

What caused Nutex Health's $52.3 million expense reduction in 2026?

The $52.3 million non-cash reduction to contract services expense resulted from a change in estimate related to the June 30, 2026 HaloMD agreement amendment and a reduction in the CMS administrative fee. It increased nine-month attributable net income by $25.0 million, or $4.83 per diluted share.

How much does Nutex Health use the independent dispute resolution process?

Approximately 50–60% of billable visits are submitted through independent dispute resolution, with 40–50% of all billable visits resulting in an award determination. Nutex Health prevailed in over 80% of determinations over the last nine months. Average collections exceeded 80% of award amounts, calculated on awards from inception through March 2026.